Google Ad

No important good thing about Umifenovir in COVID-19 remedy: Glenmark – Home Health Choices

New Delhi, Oct 9 () Drug agency Glenmark Pharmaceuticals on Friday stated the addition of antiviral Umifenovir didn’t reveal any important medical profit over Favipiravir alone in reasonable COVID-19 sufferers. The medical research evaluated the doable superiority of the mix’s efficacy in opposition to Favipiravir monotherapy, Glenmark stated in an announcement.

As per the outcomes that Glenmark introduced to the regulator, the research confirmed no superior medical outcomes with the addition of Umifenovir, it added.

This was the second medical research after the profitable Favipiravir monotherapy trial earlier this 12 months that led the corporate to receiving the Emergency Use Authorisation for Favipiravir, Glenmark stated.

“These latest findings confirm that the addition of Umifenovir does not show any incremental benefit in clinical outcomes. Thus Favipiravir therapy along with supportive care remains a suitable and effective choice for mild to moderate COVID-19 infection,” Monika Tandon Senior VP & Head, Clinical Development, Global Specialty/Branded Portfolio, Glenmark Pharmaceuticals stated. AKT BAL BAL

Latest Updates

Related Post